Vaso Corporation137 Commercial StreetPlainview, New York 11803Tel: (516) 997-4600 Fax: (516) 997-2299 Investor Contact:Jonathan NewtonInvestor RelationsPhone: 516-997-4600 Email: jnewton@vasocorporation.com PLAINVIEW,…
Signing of definitive purchase agreement represents critical next step in completing previously announced acquisitionSARASOTA, Fla. and INDIANAPOLIS, Dec. 17, 2025…
Signing of definitive purchase agreement represents critical next step in completing previously announced acquisitionSARASOTA, Fla. and INDIANAPOLIS, Dec. 17, 2025…
PONTE VEDRA, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics…
PONTE VEDRA, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics…
FRAMINGHAM, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Alira Health, a global advisory firm and CRO, today announced the appointment…
FRAMINGHAM, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Alira Health, a global advisory firm and CRO, today announced the appointment…
First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 TrialBuilds on Recent Evidence of Persistent Neuroinflammation in Alzheimer’s…
First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 TrialBuilds on Recent Evidence of Persistent Neuroinflammation in Alzheimer’s…
Emory University physician-sponsored clinical trial conducted at the Aflac Cancer and Blood Disorders Center at Children’s Healthcare of AtlantaResults demonstrated…